Abstract

Tyrosine kinase inhibitors are the standard treatment for Chronic Myeloid Leukemia. They have significantly improved the response rate and global survival in the long term for CML patients, but also added relevant and diverse toxicity. The authors report a clinical case of ocular toxicity connected to the TKIs.